dexamethasone / Generic mfg. - LARVOL DELTA

Real-World Treatment Patterns and Persistence Following Vitiligo Diagnosis in the US (AAD 2026) - "For time to second fill and time to initiation of oral dexamethasone (DEX), follow-up continued regardless of treatment changes...Among treated patients between 2017 and 2024, the most common first-line prescription therapies were topical corticosteroids (TCS; 39%), topical calcineurin inhibitors (TCI; 29%), TCS+TCI (13%), ruxolitinib (7%), and DEX (2%)...Although vitiligo treatment patterns are evolving, many patients remain untreated. Among those treated, poor persistence–marked by high discontinuation and switch rates–underscores the need for therapies offering durable disease control and sustained response."

Clinical • HEOR • Real-world • Real-world evidence • Dermatology • Dermatopathology • Immunology • Vitiligo

Outpatient Step-Up Dosing of Multiple Myeloma Bispecific Antibodies (HOPA 2026) - "Background/Rationale:All FDA-approved bispecific antibodies (BsAbs) for the treatment of multiple myeloma (MM) including teclistamab, talquetamab, and elranatamab contain prescribing information recommending inpatient admission and/or prolonged monitoring during initial step-up dosing due to the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)...Secondary objectives include: number and duration of extended-care clinic observations following SUD; number and duration of unplanned inpatient admissions following SUD; use of tocilizumab; use of dexamethasone; escalation of care events, including high-dose steroids, seizure activity, or ICU-level care; timeline of CRS and ICANS onset and resolution... Pending."

Bispecific • Clinical • CNS Disorders • Epilepsy • Hematological Malignancies • Inflammation • Multiple Myeloma

Tocilizumab Biosimilar vs. Originator for Cytokine Release Syndrome due to CAR-T or Immunotherapy (HOPA 2026) - "Background: Cytokine Release Syndrome (CRS) is a disorder caused by a large, rapid release of cytokines into the bloodstream from immune cells affected by Chimeric Antigen Receptor T-cell (CAR-T) therapy or immunotherapy (e.g., bispecific antibodies).1 Patients can develop fever, hypotension, and/or hypoxia.1 At Mount Sinai Health System (MSHS), treatment of grade 1 CRS includes an antipyretic (e.g., acetaminophen), infection workup, and tocilizumab (if high grade or recurrent fever for ≥48 hours).2 Tocilizumab is available as the originator (Actemra) and biosimilar (Tyenne), and both are FDA approved for CAR-T induced severe or life-threatening CRS.3-5 Tocilizumab is used off-label for treatment or prevention of CRS from immunotherapy, as well as prevention of CRS from CAR-T.3 Objectives: To determine the efficacy of tocilizumab biosimilar (Tyenne) vs. originator (Actemra) for hospitalized patients with CRS due to CAR-T or immunotherapy. Pending"

CAR T-Cell Therapy • Cytokine release syndrome • Hypotension • Infectious Disease • Inflammation

Oral Dexamethasone for Outpatient Management of Cytokine Release Syndrome in Patients Receiving Bispecific T-cell Engager Therapy for Multiple Myeloma (HOPA 2026) - "Background/Rationale: Four bispecific T-cell engagers (BiTEs), elranatamab, linvoseltamab, talquetamab, and teclistamab, are currently indicated for relapsed/refractory multiple myeloma.1-5 All currently available BiTEs share a US Boxed Warning of cytokine release syndrome (CRS)...Patients will be excluded if they were pregnant, had active infections, prescribed corticosteroid dose equivalent or greater than prednisone 10 mg by mouth daily, received prophylactic tocilizumab, or received BiTEs as part of a clinical trial... Results are pending. Conclusions/ This study may validate safety of outpatient management of CRS with oral dexamethasone and/or oral acetaminophen to decrease hospital admissions."

Bispecific • Clinical • Cytokine release syndrome • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma

Safety of Accelerated Premedication Schedule for Subcutaneous Daratumumab in Multiple Myeloma (HOPA 2026) - "Background: Multiple myeloma (MM) affects approximately 190,000 individuals in the United States.1 Standard frontline therapy includes daratumumab combined with an immunomodulator, a proteasome inhibitor, and dexamethasone.2 Compared with the IV formulation, subQ daratumumab significantly reduces administration-related reactions (ARRs).3 According to product labeling, premedication to prevent ARRs should be given 1–3 hours before each dose...Patients receiving IV daratumumab, receiving daratumumab for relapsed/refractory MM, with missing primary outcome data, or receiving concurrent drugs associated with substantial risk of ARR (e.g., teclistamab) will be excluded... Pending."

Clinical • Back Pain • Hematological Malignancies • Hypertension • Hypotension • Immunology • Multiple Myeloma • Musculoskeletal Pain

REAL-WORLD EXPERIENCE WITH TARLATAMAB IN PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (HOPA 2026) - "CRS was managed with acetaminophen, oxygen supplementation, and tocilizumab when indicated, while ICANS was treated with dexamethasone. Conclusion In this real-world analysis, grade 2 CRS and ICANS were the most severe toxicities observed, and clinical benefit was achieved despite these events. Oncology clinical pharmacists play a vital role in optimizing safety, clinical outcomes, and healthcare resource utilization in patients receiving BiTE therapy."

Clinical • Real-world • Real-world evidence • Infectious Disease • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Comparison of Maintenance Strategies Following Quadruplet Induction in Newly Diagnosed Myeloma (HOPA 2026) - "In the CASSIOPEIA study, patients received daratumumab maintenance or observation after daratumumab-bortezomib-thalidomide-dexamethasone induction, whereas in PERSEUS, patients received lenalidomide maintenance daratumumab-bortezomib-lenalidomide-dexamethasone induction. In progress"

Clinical • Hematological Malignancies • Multiple Myeloma

Effect of Tocilizumab on Outpatient versus Inpatient Dose Ramp up of Bispecific Antibody Agents (teclistamab, talquetamab, elranatamab, linvoseltamab) Associated Cytokine Release Syndrome (CRS), Neurotoxicity, and Hospital Admission Rates (HOPA 2026) - "Data will be collected on baseline characteristics; incidence, grade, onset, and reoccurrence of CRS and ICANs; prophylactic tocilizumab use; treatment interventions such as tocilizumab and/or dexamethasone, time to intervention; hospital admission and readmission rates; and modifications to bispecific therapy. Data analysis and results are pending."

Bispecific • Clinical • Cytokine release syndrome • Hematological Malignancies • Inflammation • Multiple Myeloma • IL6

CR16: Real-World Incidence of Infusion-Related Reactions with Sacituzumab Govitecan and Opportunities for Premedication De-escalation (HOPA 2026) - "Most patients also received the appropriate pre-medications, including diphenhydramine (98.8%), famotidine (97.6%), and acetaminophen (97.6%), along with dexamethasone (98.8%) already included in their antiemetic regimen. In this real-world cohort, no IRRs were observed with SG, suggesting greater tolerability than reported in clinical trials. Some patients tolerated premedication de-escalation, with de-escalation occurring as early as dose 3. Given the low incidences of IRRs, these findings support further investigation into developing protocols to safely reduce premedication requirements and potentially shorten observation times."

Clinical • Real-world • Real-world evidence • Breast Cancer • Solid Tumor

Evaluation of VTE Prophylaxis in Patients Receiving Immunomodulators for Multiple Myeloma (HOPA 2026) - "When IMiDs are combined with high-dose dexamethasone, the risk of VTE increases by two- to threefold, with event rates reaching up to 25% in the absence of appropriate prophylaxis... Pending"

Clinical • Immunomodulating • Hematological Malignancies • Multiple Myeloma • Venous Thromboembolism

CR07: Dexamethasone versus Tocilizumab for Management of Talquetamab-induced Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma: A Multicenter, Retrospective Study (HOPA 2026) - "Although more patients experienced recurrent CRS with dexamethasone compared to tocilizumab, subsequent events were low-grade and generally manageable with repeated dexamethasone doses. Dexamethasone could be an alternative treatment option to tocilizumab for low-grade talquetamab-induced CRS."

Cytokine release syndrome • Retrospective data • Hematological Malignancies • Inflammation • Multiple Myeloma

CR06: Incidence of CMV-Reactivation in Multiple Myeloma Patients Receiving Bispecific Antibodies (HOPA 2026) - " This multi-center, retrospective review included 555 patients who received teclistamab, elranatamab, or talquetamab...Age, number of prior lines of therapy, prior BCMA-directed therapy, max grade CRS, tocilizumab treatment, dexamethasone treatment, use of IVIG, and IgG levels at day 30 and 90 were evaluated via logistic regression; it was found that none of the above factors predicted CMV reactivation. CMV reactivation occurred in almost a quarter of CMV seropositive patients receiving bispecific antibodies for RRMM, with 33% of those patients requiring CMV-directed therapy. This incidence reflects the need for additional guidance for risk stratification, monitoring, and prophylactic strategies in this high-risk patient population."

Bispecific • Clinical • Cytomegalovirus Infection • Hematological Malignancies • Infectious Disease • Multiple Myeloma

Omission of Daratumumab-Hyaluronidase Premedication and Quantifying Rate of Infusion-Related Reactions (HOPA 2026) - "If patients receive only dexamethasone without any other premedication, they will be included in the premedication omission group since dexamethasone is often part of the treatment regimen and is not used solely as a premedication for daratumumab. Not available at this time. Results pending. Conclusion/ Not available at this time."

Amyloidosis • Hematological Malignancies • Multiple Myeloma

CR14: Outcomes of Supportive Care versus Pharmacologic Intervention for Management of CRS in RRMM Treated with BCMA- and GPRC5D-Directed Bispecifics (HOPA 2026) - " This retrospective study included 555 RRMM patients from 7 US academic centers who initiated elranatamab, teclistamab, or talquetamab by March 2025...Recurrent CRS in all groups as at the same or lower grade except for one patient treated with both dexamethasone and tocilizumab who had grade 1 CRS with SUD1 and grade 2 CRS with SUD2. Supportive care alone demonstrated similar outcomes to pharmacologic intervention for low-grade CRS, particularly grade 1, supporting its role as a safe, effective initial management strategy that may limit the need for additional intervention."

Bispecific • Inflammation • Multiple Myeloma

Optimizing Early Recognition and Pharmacologic Management Pathways for Pediatric T-Lymphoblastic Lymphoma Presenting With Mediastinal Compression in a Hematology/Oncology Service. (HOPA 2026) - "Pharmacy processes assessed included availability of induction agents (dexamethasone, CAL-asparaginase, bortezomib), timing of pericardiocentesis and thoracentesis support medications, and chemotherapy verification workflows...Application of these findings led COG to the construction of a unified pharmacist-supported pathway in the upcoming AALL2331 study for newly diagnosed T-LL prioritizing: (1) Prednisone-based induction, (2) Bortezomib during induction and delayed intensification, (3) elimination of prophylactic cranial radiation, (4) enhanced toxic-effect monitoring for pancreatitis, thrombosis, and early remission death risks, and (5) exploring the role of Daratumomab at first presentation of T-LL...Integration of updated COG data supports structured decision-making and reduction of treatment delays. Standardizing pharmacy workflows may decrease morbidity associated with airway compromise and improve adherence to contemporary evidence-based regimens."

Clinical • Cardiovascular • Hematological Disorders • Hematological Malignancies • Lymphoblastic Lymphoma • Lymphoma • Pancreatitis • Pediatrics • T Acute Lymphoblastic Leukemia • Thrombosis

Comparison of Low- versus Standard-Dose Dexamethasone for the Prevention of Docetaxel-Associated Peripheral Edema in Breast Cancer Patients (HOPA 2026) - "To be determined"

Clinical • Breast Cancer • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Diabetes • Heart Failure • Hepatology • Immunology • Insomnia • Liver Failure • Nephrology • Oncology • Renal Disease • Sleep Disorder • Solid Tumor

Death by Dex: Pneumocystis jirovecii Pneumonia in the Era of Dara-RVd for Multiple Myeloma (HOPA 2026) - "Notably, the PERSEUS (2024) and phase 2 GRIFFIN (2020) clinical trials established the quadruplet regimen Dara-RVd, which combines daratumumab with lenalidomide, bortezomib, and dexamethasone for the first-line treatment of MM. Results are pending. Study findings and conclusions will be presented at the HOPA Annual Conference."

Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Pneumonia • Respiratory Diseases

Standard vs. Lower Dose Dexamethasone for the Prevention of Docetaxel-Related Hypersensitivity Reactions and Fluid Retention in Solid Malignancies (HOPA 2026) - "The incidence of FR and HSRs will be estimated using a simple test of proportions. Log-binomial regression models will be used to generate the adjusted relative risks and associated 95% confidence intervals of the treatment effects.6 Results/Discussion/Conclusion Pending"

Hypotension • Immunology • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor

Usage of Prophylactic Dexamethasone to Reduce Incidence and Severity of Toxicity after Ciltacabtagene autoleucel (HOPA 2026) - "Results pending."

Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Inflammation • Multiple Myeloma

North American Enrollment in Clinical Trials: An Emerging Issue for Regulatory Approval (HOPA 2026) - "In the Asian region, the median OS was not estimable for glofitamab plus gemcitabine and oxaliplatin versus 8.2 months in rituximab plus gemcitabine and oxaliplatin.1 In the rest of the world, the median OS was 21.2 months for glofitamab plus gemcitabine and oxaliplatin versus 27.8 months for rituximab plus gemcitabine and oxaliplatin.1 Even when excluding the OS data, which could be confounded by subsequent therapy, the pooled non-Asian patient data (ie, in United States, Europe, Australia) found glofitamab plus gemcitabine and oxaliplatin did not have significantly longer PFS than with rituximab plus gemcitabine and oxaliplatin.1 The Asian population had more lenalidomide exposure and only 2 of the 131 patients previously received CAR T therapy compared with 19 of 143 patients from the rest of the world.1 In the United States, CAR T therapy is standard of care second- or third-line therapy, whereas there is limited or no access to CAR T therapy in Asia3 Was this an..."

Clinical • B Cell Lymphoma • Breast Cancer • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Genito-urinary Cancer • Hematological Malignancies • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Leukemia • Lung Cancer • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor • HER-2

CMV Reactivation With Bispecific Antibodies in Multiple Myeloma (HOPA 2026) - " This multicenter, retrospective review included 555 patients who received teclistamab, elranatamab, or talquetamab...Age, the number of previous lines of therapy, previous BCMA-directed therapy, maximum-grade cytokine release syndrome, tocilizumab treatment, dexamethasone treatment, use of IVIG, and IgG levels at day 30 and day 90 were evaluated via logistic regression; none of the above factors predicted CMV reactivation. CMV reactivation occurred in almost 25% of patients who are CMV seropositive and receiving bispecific antibodies for RRMM, with 33% of those patients requiring CMV-directed therapy. This incidence reflects the need for additional guidance for risk stratification, monitoring, and prophylactic strategies in this high-risk patient population."

Bispecific • Cytomegalovirus Infection • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma

Real-World Incidence of Infusion-Related Reactions With Sacituzumab Govitecan and Opportunities for Premedication De-Escalation (HOPA 2026) - "Most patients also received the appropriate premedications, including diphenhydramine (98.8%), famotidine (97.6%), and acetaminophen (97.6%), along with dexamethasone (98.8%) already included in their antiemetic regimen. In this real-world cohort, no IRRs were observed with sacituzumab govitecan, which suggests greater tolerability than in clinical trials. Some patients tolerated premedication de-escalation, with de-escalation occurring as early as dose 3. Given the low incidences of IRRs, these findings support further investigation into developing protocols to safely reduce premedication requirements and potentially shorten observation times."

Clinical • Real-world • Real-world evidence • Breast Cancer • Solid Tumor

Dexamethasone Versus Tocilizumab for Management of Talquetamab-Induced Cytokine Release Syndrome in Patients With Relapsed/Refractory Multiple Myeloma: A Multicenter, Retrospective Study (HOPA 2026) - "Although more patients had recurrent CRS with dexamethasone than with tocilizumab, subsequent events were low grade and generally manageable with repeated dexamethasone doses. Dexamethasone could be an alternative treatment option to tocilizumab for low-grade talquetamab-induced CRS. Rodriguez-Otero P, Usmani S, Cohen AD, et al."

Cytokine release syndrome • Retrospective data • Hematological Malignancies • Inflammation • Multiple Myeloma

Outcomes of Supportive Care Versus Pharmacologic Intervention for the Management of CRS in Relapsed or Refractory Multiple Myeloma Treated With BCMA- and GPRC5D-Directed Bispecifics (HOPA 2026) - " This retrospective study included 555 patients with relapsed or refractory multiple myeloma from 7 US academic centers that initiated elranatamab, teclistamab, or talquetamab by March 2025...Recurrent CRS in all groups was at the same or lower grade, except for 1 patient who received dexamethasone and tocilizumab and had grade 1 CRS with SUD 1 and grade 2 CRS with SUD 2. Supportive care alone demonstrated similar outcomes to pharmacologic intervention for low-grade CRS, particularly grade 1, which supports its role as a safe, effective initial management strategy that may limit the need for additional intervention."

Bispecific • Hematological Malignancies • Inflammation • Multiple Myeloma

Diffuse Large B-Cell Lymphoma Presenting with Cutaneous and Subcutaneous Nodules (AAD 2026) - "After three cycles, progression was confirmed, and therapy was switched to rituximab, gemcitabine, dexamethasone, and carboplatin; unfortunately, the patient subsequently passed away. This diagnosis represents a category of exclusion for cases not fitting defined subgroups. Primary cutaneous diffuse large B-cell lymphoma, leg type, was considered; however, immunohistochemistry was inconsistent and extracutaneous involvement was present.2 Standard frontline therapy is R-CHOP, with second-line regimens pursued in cases of treatment failure, as demonstrated here."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Lymphoma • Metabolic Disorders • Non-Hodgkin’s Lymphoma • Otorhinolaryngology • Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type • BCL2 • BCL6 • CD20 • CD5 • IRF4